Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders. Speaking at H.C. Wainwright’s 28th Annual Global Investment Conference, Chief Executive Officer Chris Anzalone said the company has evolved from its […]